



**BlueCross  
BlueShield**

Federal Employee Program

**DARZALEX FASPRO  
PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: 1-877-378-4727

Patient Information (required)				Provider Information (required)		
Date:				Provider Name:		
Patient Name:				Specialty:		NPI:
Date of Birth:	Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female			Office Phone:		Office Fax:
Street Address:				Office Street Address:		
City:	State:	Zip:		City:	State:	Zip:
Patient ID:	R <input type="text"/>			Physician Signature:		
<b>PHYSICIAN COMPLETES</b>						

**Darzalex Faspro**

(daratumumab and hyaluronidase-fihj)

**\*\*Check [www.fepblue.org/formulary](http://www.fepblue.org/formulary) to confirm which medication is part of the patient's benefit**

**NOTE: Form must be completed in its entirety for processing**

Is this request for brand or generic? ☐ Brand ☐ Generic

1. What is the patient's diagnosis?

☐ Multiple Myeloma (MM)

a. Has the patient been on Darzalex Faspro continuously for the last **6 months**, excluding samples? *Please select answer below:*

☐ **NO** – this is **INITIATION** of therapy, please answer the following questions:

i. Is the multiple myeloma newly diagnosed? *Please select answer below:*

☐ **Yes:** Is the patient eligible for autologous stem cell transplant? *Please select answer below:*

☐ **Yes:** Will Darzalex Faspro be used in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone? ☐ Yes ☐ No\*

*\*If NO*, will Darzalex Faspro be used in combination with bortezomib (Velcade), thalidomide, and dexamethasone? ☐ Yes ☐ No

☐ **No:** Will Darzalex Faspro be used in combination with bortezomib (Velcade), melphalan, and prednisone? ☐ Yes ☐ No\*

*\*If NO*, will Darzalex Faspro be used in combination with lenalidomide (Revlimid) and dexamethasone? ☐ Yes ☐ No

☐ **No:** Please answer the following questions:

1) Will Darzalex Faspro be used as monotherapy? ☐ Yes\* (*\*If YES, answer the following questions*) ☐ No

a) Has the patient received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory agent? ☐ Yes ☐ No

b) Has the patient had a double-refractory failure to a proteasome inhibitor (PI) and an immunomodulatory agent? ☐ Yes ☐ No

2) Will Darzalex Faspro be used in combination with carfilzomib (Kyprolis) and dexamethasone? ☐ Yes\* ☐ No

*\*If YES*, please answer the following questions:

a) Does the patient have relapsed or refractory multiple myeloma? ☐ Yes ☐ No

b) Has the patient received one to three prior lines of therapy? ☐ Yes ☐ No

3) Will Darzalex Faspro be used in combination with lenalidomide (Revlimid) and dexamethasone? ☐ Yes\* ☐ No

*\*If YES*, please answer the following questions:

a) Does the patient have relapsed or refractory multiple myeloma? ☐ Yes ☐ No

b) Has the patient received at least one prior therapy? ☐ Yes ☐ No

4) Will Darzalex Faspro be used in combination with bortezomib (Velcade) and dexamethasone? ☐ Yes\* ☐ No

*\*If YES*, has the patient received at least one prior therapy? ☐ Yes ☐ No

5) Will Darzalex Faspro be used in combination with pomalidomide (Pomalyst) and dexamethasone? ☐ Yes\* ☐ No

*\*If YES*, has the patient received at least one prior therapy, including lenalidomide (Revlimid) and a proteasome inhibitor (PI)? ☐ Yes ☐ No

☐ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

i. Has the patient experienced disease progression or unacceptable toxicity while on Darzalex Faspro? ☐ Yes ☐ No

**PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL DIAGNOSES**

**PAGE 1 of 2**

The information provided on this form will be used to determine the provision of healthcare benefits under a U.S. federal government program, and any falsification of records may subject the provider to prosecution, either civilly or criminally, under the False Claim Acts, the False Statements Act, the mail or wire fraud statutes, or other federal or state laws prohibiting such falsification. **Prescriber Certification:** I certify all information provided on this form to be true and correct to the best of my knowledge and belief. I understand that the insurer may request a medical record if the information provided herein is not sufficient to make a benefit determination or requires clarification and I agree to provide any such information to the insurer. Darzalex Faspro – FEP MD Fax Form Revised 9/6/2024



**BlueCross  
BlueShield**

Federal Employee Program

**DARZALEX FASPRO  
PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: 1-877-378-4727

**PAGE 2 - PHYSICIAN COMPLETES**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Patient ID: R \_\_\_\_\_

☐ Light chain (AL) amyloidosis

a. Does the patient have NYHA Class IIIB or Class IV cardiac disease? ☐ Yes ☐ No

b. Does the patient have Mayo Stage IIIB light chain (AL) amyloidosis? ☐ Yes ☐ No

c. Is this **INITIATION** or **CONTINUATION** of therapy? *Please select answer below:*

☐ **INITIATION** of therapy, please answer the following questions:

i. Is the light chain (AL) amyloidosis newly diagnosed? ☐ Yes ☐ No

ii. Will Darzalex Faspro be used in combination with bortezomib (Velcade), cyclophosphamide, and dexamethasone? ☐ Yes ☐ No

☐ **CONTINUATION** of therapy (**PA renewal**), please answer the following question:

i. Has the patient experienced disease progression or unacceptable toxicity while on Darzalex Faspro? ☐ Yes ☐ No

☐ None of the above

**PAGE 2 of 2**



Federal Employee Program.

**DARZALEX FASPRO  
PRIOR APPROVAL REQUEST**

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: **1-877-378-4727**

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

<b>Electronically Online</b> (ePA) <b>Results in 2-3 minutes</b> <b>FASTEST AND EASIEST</b>	Now you can get responses to drug Prior Authorization requests <b>securely</b> online. <b>Online</b> submissions may receive <b>instant</b> responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to <b>Caremark.com/ePA</b> .
<b>Phone</b> (4-5 minutes for response)	The FEP Clinical Call Center can be reached at <b>(877)-727-3784</b> between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same information contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
<b>Fax</b> (3-5 days for response)	Fax the attached form to <b>(877)-378-4727</b> . Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the Prior Authorization request cannot be processed. <b><u>Please only fax the completed form once as duplicate submissions may delay processing times.</u></b>

<b>faster...</b>	Introducing ePA! Online Prior Authorizations in minutes through Caremark.com/ePA. Sign up today!
<b>easier...</b>	
<b>better...</b>	
<b>CVS/caremark</b> 	